Andrei H Iagaru

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi request reprint Demonstration of a right inguinal hernia containing urinary bladder diverticulum on whole-body bone scan and pelvic CT
    Andrei Iagaru
    Department of Radiology, Division of Nuclear Medicine, Stanford University School of Medicine, 300 Pasteur Dr, Room H 0101, Stanford, CA 94305, USA
    Eur J Nucl Med Mol Imaging 33:234. 2006
  2. doi request reprint Imaging tumor angiogenesis: the road to clinical utility
    Andrei Iagaru
    Department of Radiology, Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Dr, Rm H 0101, Stanford, CA 94305, USA
    AJR Am J Roentgenol 201:W183-91. 2013
  3. doi request reprint Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, Stanford, CA, USA
    Clin Nucl Med 38:e290-6. 2013
  4. doi request reprint Combined 18F-fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trial
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, Stanford, California 94305, USA
    J Nucl Med 54:176-83. 2013
  5. doi request reprint Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases
    Andrei Iagaru
    Department of Radiology, Division of Nuclear Medicine, Stanford University Medical Center, Stanford, CA 94305, USA
    Mol Imaging Biol 14:252-9. 2012
  6. ncbi request reprint Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma
    Andrei Iagaru
    Stanford University Medical Center, Division of Nuclear Medicine, Stanford, CA 94305, USA
    Hell J Nucl Med 12:26-9. 2009
  7. ncbi request reprint (18)F-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan?
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Dr, Room H 0101, Stanford, CA 94305 5427, USA
    Hell J Nucl Med 11:153-6. 2008
  8. ncbi request reprint F-18 FDG PET visualization of urinary leak after nephrostomy tube removal
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, Stanford, CA 94305, USA
    Clin Nucl Med 32:168-9. 2007
  9. doi request reprint FDG-PET/CT in cancers of the head and neck: what is the definition of whole body scanning?
    Andrei Iagaru
    Stanford Hospital and Clinics, Division of Nuclear Medicine, 300 Pasteur Dr, Room H 0101, Stanford, CA 94305, USA
    Mol Imaging Biol 13:362-7. 2011
  10. pmc 18F-FDG PET/CT evaluation of patients with ovarian carcinoma
    Andrei H Iagaru
    Department of Radiolog, Stanford Hospital and Clinics, Stanford, CA, USA
    Nucl Med Commun 29:1046-51. 2008

Detail Information

Publications40

  1. ncbi request reprint Demonstration of a right inguinal hernia containing urinary bladder diverticulum on whole-body bone scan and pelvic CT
    Andrei Iagaru
    Department of Radiology, Division of Nuclear Medicine, Stanford University School of Medicine, 300 Pasteur Dr, Room H 0101, Stanford, CA 94305, USA
    Eur J Nucl Med Mol Imaging 33:234. 2006
  2. doi request reprint Imaging tumor angiogenesis: the road to clinical utility
    Andrei Iagaru
    Department of Radiology, Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Dr, Rm H 0101, Stanford, CA 94305, USA
    AJR Am J Roentgenol 201:W183-91. 2013
    ..The ability to noninvasively visualize angiogenesis may provide new opportunities to more appropriately select patients for antiangiogenesis treatment and to monitor treatment efficacy...
  3. doi request reprint Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, Stanford, CA, USA
    Clin Nucl Med 38:e290-6. 2013
    ..The aim of this study was to compare 99mTc-MDP bone scanning, 18F NaF PET/CT, 18F FDG PET/CT, and whole-body MRI (WBMRI) for detection of known osseous metastases...
  4. doi request reprint Combined 18F-fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trial
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, Stanford, California 94305, USA
    J Nucl Med 54:176-83. 2013
    ..We prospectively evaluated combined (18)F(-)/(18)F-FDG as a single PET/CT examination for evaluation of cancer patients and compared it with separate (18)F(-) PET/CT and (18)F-FDG PET/CT scans...
  5. doi request reprint Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases
    Andrei Iagaru
    Department of Radiology, Division of Nuclear Medicine, Stanford University Medical Center, Stanford, CA 94305, USA
    Mol Imaging Biol 14:252-9. 2012
    ..There are few prospective studies comparing these three methods of detection of skeletal metastases. Thus, we were prompted to initiate this prospective pilot trial...
  6. ncbi request reprint Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma
    Andrei Iagaru
    Stanford University Medical Center, Division of Nuclear Medicine, Stanford, CA 94305, USA
    Hell J Nucl Med 12:26-9. 2009
    ..The emergence of the combined PET/CT scanner enhanced the accuracy of the imaging procedure in view of the precise anatomic localization of metabolic abnormalities...
  7. ncbi request reprint (18)F-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan?
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Dr, Room H 0101, Stanford, CA 94305 5427, USA
    Hell J Nucl Med 11:153-6. 2008
    ..80 in group B. Results of PET/CT after 2 cycles of chemotherapy did not statistically differ from the results of PET/CT after 4 cycles of chemotherapy. These results need to be confirmed in larger, prospective, randomized trials...
  8. ncbi request reprint F-18 FDG PET visualization of urinary leak after nephrostomy tube removal
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, Stanford, CA 94305, USA
    Clin Nucl Med 32:168-9. 2007
  9. doi request reprint FDG-PET/CT in cancers of the head and neck: what is the definition of whole body scanning?
    Andrei Iagaru
    Stanford Hospital and Clinics, Division of Nuclear Medicine, 300 Pasteur Dr, Room H 0101, Stanford, CA 94305, USA
    Mol Imaging Biol 13:362-7. 2011
    ..e., eyes to thighs) may yield little additional information. Therefore, we were prompted to review our experience with PET/computed tomography (CT) in the management of patients with HNSCC and NPC...
  10. pmc 18F-FDG PET/CT evaluation of patients with ovarian carcinoma
    Andrei H Iagaru
    Department of Radiolog, Stanford Hospital and Clinics, Stanford, CA, USA
    Nucl Med Commun 29:1046-51. 2008
    ..Therefore, we were prompted to review our experience with PET/CT in the management of patients with ovarian carcinoma...
  11. doi request reprint 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
    Mol Imaging Biol 12:198-203. 2010
    ..Both target CD20 receptors present on the surface of lymphocytes. We present our clinical experience with Bexxar and Zevalin in the management of low-grade refractory or relapsed NHL...
  12. doi request reprint 90Y-ibritumomab therapy in refractory non-Hodgkin's lymphoma: observations from 111In-ibritumomab pretreatment imaging
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, Stanford, California 94305, USA
    J Nucl Med 49:1809-12. 2008
    ..90Y-ibritumomab is an antibody targeting CD20 receptors on the surface of lymphocytes. We present observations from our clinical experience with 90Y-ibritumomab in the management of NHL...
  13. ncbi request reprint Demonstration of an ectopic mediastinal parathyroid adenoma on Tc-99m sestamibi myocardial perfusion scintigraphy
    Andrei Iagaru
    Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine, LosAngeles, Calif, USA
    J Nucl Cardiol 13:719-21. 2006
  14. ncbi request reprint PET/CT follow-up in nonossifying fibroma
    Andrei Iagaru
    Keck School of Medicine, University of Southern California, PET Imaging Science Center, Los Angeles, CA, USA
    AJR Am J Roentgenol 187:830-2. 2006
  15. ncbi request reprint F-18 FDG PET imaging of urinary bladder oat cell carcinoma with widespread osseous metastases
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, VA Palo Alto Health Care System, Stanford, California 94305, USA
    Clin Nucl Med 31:476-8. 2006
  16. ncbi request reprint F-18 FDG PET evaluation of bronchial plasmacytoma with CT and MRI correlation
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, VA Palo Alto Health Care System, Stanford, CA 94305, USA
    Clin Nucl Med 31:279-80. 2006
  17. ncbi request reprint Failed atrial septal defect repair versus pulmonary hypertension with right ventricular failure
    Andrei Iagaru
    Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    Clin Nucl Med 30:767-8. 2005
  18. doi request reprint Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT
    Marnix G E H Lam
    Division of Interventional Radiology, Stanford University School of Medicine, Stanford, California
    J Nucl Med 54:2055-61. 2013
    ..Planning hepatic (90)Y radioembolization activity requires balancing toxicity with efficacy. We developed a dual-tracer SPECT fusion imaging protocol that merges data on radioactivity distribution with physiologic liver mapping...
  19. pmc Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels
    Erik S Mittra
    Molecular Imaging Program, Department of Radiology, Division of Nuclear Medicine, Stanford Hospital and Clinics, 300 Pasteur Dr, Room H2200, Stanford, CA 94305 5281, USA
    Radiology 260:182-91. 2011
    ....
  20. doi request reprint Perspectives of molecular imaging and radioimmunotherapy in lymphoma
    Andrei Iagaru
    Department of Radiology, Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Room H 0101, Stanford, CA 94305 5427, USA
    Radiol Clin North Am 46:243-52, viii. 2008
    ..Finally, we discuss advances in molecular imaging that may herald the next generation of PET radiotracers after 18F FDG...
  21. doi request reprint Response to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [18F]fluorodeoxyglucose positron emission tomography and computed tomography
    Daniel Y Sze
    Division of Interventional Radiology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Hum Gene Ther 23:91-7. 2012
    ..More sophisticated molecular imaging will need to be developed to monitor the effects of this novel class of antineoplastic agents...
  22. ncbi request reprint F-18 FDG PET/CT evaluation of osseous and soft tissue sarcomas
    Andrei Iagaru
    Division of Nuclear Medicine, Department of Radiology, Stanford Hospital and Clinics, Stanford, California, USA
    Clin Nucl Med 31:754-60. 2006
    ..Therefore, we were prompted to review our experience with F-18 FDG PET/CT in OSTS...
  23. doi request reprint Thyroid stunning: fact or fiction?
    I Ross McDougall
    Division of Nuclear Medicine and Molecular Imaging, Stanford University Hospital and Clinics, Stanford, CA, USA
    Semin Nucl Med 41:105-12. 2011
    ..Larger diagnostic doses and longer delays to therapy appear to increase the likelihood of stunning. The stunning effect of early-absorbed radiation from the therapy should also be considered...
  24. doi request reprint Root cause analysis of gastroduodenal ulceration after yttrium-90 radioembolization
    Marnix G E H Lam
    Division of Interventional Radiology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA, 94305, USA
    Cardiovasc Intervent Radiol 36:1536-47. 2013
    ..We aimed to identify the risk factors in the treated population and to determine the specific mechanism of nontarget RE in individual cases...
  25. doi request reprint Safety of repeated yttrium-90 radioembolization
    Marnix G E H Lam
    Division of Interventional Radiology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA, 94305 5642, USA
    Cardiovasc Intervent Radiol 36:1320-8. 2013
    ..We performed a retrospective safety analysis on patients who underwent repeated RE...
  26. ncbi request reprint F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas
    Andrei Iagaru
    PET Imaging Science Center, Keck School of Medicine of USC, Los Angeles, CA 90033, USA
    Clin Nucl Med 33:8-13. 2008
    ..A review of our experience with PET in assessing therapy response in osseous and soft tissue sarcomas (OSTS) is presented...
  27. ncbi request reprint FDG PET-CT demonstration of Sjogren's sialoadenitis
    Hossein Jadvar
    Department of Radiology, Division of Nuclear Medicine, PET Imaging Science Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Clin Nucl Med 30:698-9. 2005
    ..CT transmission scan was obtained for attenuation correction. PET-CT demonstrated no evidence of hypermetabolic nodal disease but showed symmetric intensely hypermetabolic submandibular and parotid salivary glands...
  28. ncbi request reprint F-18 FDG PET/CT in the management of thyroid cancer
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University School of Medicine, Stanford, California 94305, USA
    Clin Nucl Med 32:690-5. 2007
    ..We reviewed our experience with F-18 FDG PET/CT in thyroid cancer, with an emphasis on correlation with Tg, and maximum standardized uptake values (SUV). We also analyzed the role of thyroid stimulating hormone (TSH) on PET/CT results...
  29. ncbi request reprint Advances in metabolic imaging for surgical oncology
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Room H 0101, Stanford, CA 94305, USA
    Surg Oncol Clin N Am 16:273-92. 2007
    ..Finally, advances in molecular imaging that may herald the next generation of PET radiotracers beyond (18)F FDG are reviewed...
  30. doi request reprint Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, Stanford, California, USA
    J Nucl Med 50:501-5. 2009
    ..Sodium (18)F was previously used for bone imaging and can be used as a PET/CT skeletal tracer. The combined administration of (18)F and (18)F-FDG in a single PET/CT study for cancer detection has not been reported to date...
  31. pmc Validation that metabolic tumor volume predicts outcome in head-and-neck cancer
    Chad Tang
    Department of Radiation Oncology, Stanford University, Stanford, CA, USA
    Int J Radiat Oncol Biol Phys 83:1514-20. 2012
    ....
  32. ncbi request reprint 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas
    Andrei Iagaru
    PET Imaging Science Center, Keck School of Medicine of USC, Los Angeles, CA 90033, USA
    Nucl Med Commun 27:795-802. 2006
    ..However, PET appears to be less accurate in detection of pulmonary metastases. We were therefore prompted to review our experience with PET and PET/computed tomography (CT) in osseous and soft tissue sarcomas (OSTSs)...
  33. ncbi request reprint Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT
    Andrei Iagaru
    PET Imaging Science Center, Department of Radiology, University of Southern California, Keck School of Medicine of USC, 1510 San Pablo St, Suite 350, Los Angeles, CA 90033, USA
    Mol Imaging Biol 9:72-7. 2007
    ..However, controversies exist regarding its ability to reliably assess recurrent medullary thyroid cancer (MTC). We were therefore prompted to review our experience with FDG-PET for detection of occult MTC...
  34. ncbi request reprint F-18 FDG PET/CT demonstration of an adrenal metastasis in a patient with anaplastic thyroid cancer
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, Stanford, California 94305, USA
    Clin Nucl Med 32:13-5. 2007
    ..An adrenal metastasis was identified on an F-18 FDG PET/CT scan in a patient with anaplastic thyroid cancer. There are very few reports of thyroid cancer, even anaplastic thyroid cancer, metastasizing to the adrenal...
  35. pmc An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatment-naive non-small cell lung cancer
    Viswam S Nair
    Division of Pulmonary and Critical Care Medicine, Stanford University School of Medicine, Stanford, California, USA
    PLoS ONE 8:e67733. 2013
    ....
  36. doi request reprint Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolization
    John D Louie
    Department of Radiology, Stanford University Medical Center, CA 94305 5642, USA
    J Vasc Interv Radiol 20:606-13. 2009
    ..The present study was performed to determine if cone-beam computed tomography (CBCT) affects treatment planning as an adjunct to these conventional imaging modalities...
  37. ncbi request reprint 123I MIBG mapping with intraoperative gamma probe for recurrent neuroblastoma
    Andrei Iagaru
    Department of Radiology, Division of Nuclear Medicine, Stanford University Medical Center, Stanford, CA 94305 5427, USA
    Mol Imaging Biol 10:19-23. 2008
    ..Intraoperative gamma probe mapping of the liver identified areas with signal above the background, but these were prove to be hemosiderin deposits on histo-pathology examination...
  38. ncbi request reprint Breast MRI and 18F FDG PET/CT in the management of breast cancer
    Andrei Iagaru
    PET Imaging Science Center, Keck School of Medicine of USC, 1510 San Pablo St, Suite 350, Los Angeles, CA 90033, USA
    Ann Nucl Med 21:33-8. 2007
    ..We were therefore prompted to review our experience with PET and BMRI in BC...
  39. ncbi request reprint 2-Deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and positron emission tomography/computed tomography diagnosis of patients with recurrent papillary thyroid cancer
    Andrei Iagaru
    PET Imaging Science Center, Keck School of Medicine of USC, 1510 San Pablo Street, Suite 350, Los Angeles, CA, 90033, USA
    Mol Imaging Biol 8:309-14. 2006
    ..We were therefore prompted to review our experience with FDG-PET in detection of recurrent papillary thyroid cancer (PTC)...
  40. ncbi request reprint Molecular imaging can accelerate anti-angiogenic drug development and testing
    Andrei Iagaru
    Stanford University School of Medicine, Stanford, CA, USA
    Nat Clin Pract Oncol 4:556-7. 2007